This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (11)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Thrombolysis  • Venous Thromboembolism  • Cardiovascular System  • Alert me on articles by topic  Social Bookmarking   What's this?

Con

Gabriel Thabut, MD; Damien Logeart, MD

Arch Intern Med. 2005;165:2200-2203.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

Although the mortality rate for those with acute PE is low, certain patients are at high risk.¹ Therefore, optimal management strategies should rely on risk stratification rather than "one-size-fits-all" treatment.² In high-risk patients, the use of aggressive treatment could be justified. Despite the lack of definitive evidence,³ massive PE associated with cardiogenic shock, given the high mortality rate, is a widely accepted indication for thrombolysis.^4-5 At the other extreme, the risks of thrombolysis are not justified in patients with an anatomically small PE that causes no elevation in RV afterload. The mortality rate for these patients is low, with most patients dying from underlying conditions rather than from PE.⁶ In a meta-analysis of 5 studies involving 1302 patients with PE treated by heparin followed by warfarin, the rate of death due to PE was only 1.5%.⁷ In such patients, the expected improvement in survival . . . [Full Text of this Article]

IS RV DYSFUNCTION AN INDEPENDENT PROGNOSTIC FACTOR IN PATIENTS WITH PE?

SHOULD THE HEMODYNAMIC BENEFITS OF TREATMENT OF PE TRANSLATE INTO CLINICAL BENEFIT?

WHAT IS THE PROVEN BENEFIT OF THROMBOLYTIC AGENTS IN PATIENTS WITH ACUTE PE AND RV DYSFUNCTION?

FUTURE DIRECTIONS

AUTHOR INFORMATION

Author Affiliations: Service de Pneumologie et Réanimation Respiratoire (Dr Thabut), and Service de Cardiologie (Dr Logeart), Hôpital Beaujon, Clichy, France.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Thrombolytic Therapy for Patients With Pulmonary Embolism Who Are Hemodynamically Stable But Have Right Ventricular Dysfunction: Pro
Samuel Z. Goldhaber
Arch Intern Med. 2005;165(19):2197-2199.
EXTRACT | FULL TEXT  

Rebuttal
Samuel Z. Goldhaber
Arch Intern Med. 2005;165(19):2204.
EXTRACT | FULL TEXT  

Rebuttal
Gabriel Thabut and Damien Logeart
Arch Intern Med. 2005;165(19):2204-2205.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Prospective Evaluation of Right Ventricular Function and Functional Status 6 Months After Acute Submassive Pulmonary Embolism: Frequency of Persistent or Subsequent Elevation in Estimated Pulmonary Artery Pressure
Kline et al.
Chest 2009;136:1202-1210.
ABSTRACT | FULL TEXT  

Echocardiographic and functional cardiopulmonary problems 6 months after first-time pulmonary embolism in previously healthy patients
Stevinson et al.
Eur Heart J 2007;28:2517-2524.
ABSTRACT | FULL TEXT